Bisphosphonate exposure and atypical fracture risk…

The issue of certain bone building medicines (alendronate, zolendronic acid and others termed  “bisphosphonates”) used to reduce fracture risk in people with thin bones (osteopenia or osteoporosis) as being associated with atypical hip fractures has been in the news alot lately.  The attached study and others seem to suggest that for now, the benefits of taking bisphosphate therapy still outweigh the risks in people with increased fracure risk.  An additional approach may be to distinguish between low vs high bone turnover osteoporosis (and approach treatment from an osteoblast stimulation vs osteoclast inhibition perspective respectively).

More from NEJM:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s